NCT03447379View on ClinicalTrials.gov

Short-term Dual Antiplatelet Therapy After Deployment of Bioabsorbable Polymer Everolimus-eluting Stent

NACompletedINTERVENTIONAL

Enrollment

1,452

Participants

Timeline

Start Date

December 15, 2017

Primary Completion Date

March 3, 2022

Study Completion Date

August 17, 2022

Conditions

Coronary Artery Disease

Interventions

DRUG

P2Y12 antagonist monotherapy

P2Y12 inhibitor(Clopidogrel 75mg/day or Ticagrelor 180mg/day) for 9months after 3 months of DAPT(Aspirin 100mg/day + Clopidogrel 75mg/day or Aspirin 100mg/day + Ticagrelor 180mg/day)

DRUG

Aspirin plus P2Y12 antagonist

DAPT(Aspirin 100mg/day + Clopidogrel 75mg/day or Aspirin 100mg/day + Ticagrelor 180mg/day) for a year

Trial Locations (1)

Unknown

Gangnam Severance Hospital, Seoul

All Listed Sponsors

lead

Gangnam Severance Hospital

OTHER

NCT03447379 - Short-term Dual Antiplatelet Therapy After Deployment of Bioabsorbable Polymer Everolimus-eluting Stent | Biotech Hunter | Biotech Hunter